Skip to main content
Erschienen in: Annals of Surgical Oncology 10/2012

01.10.2012 | Breast Oncology

Cost Comparison of Radiation Treatment Options After Lumpectomy for Breast Cancer

verfasst von: Rachel A. Greenup, MD, MPH, Melissa S. Camp, MD, MPH, Alphonse G. Taghian, MD, PhD, Julliette Buckley, MD, Suzanne B. Coopey, MD, Michele Gadd, MD, Kevin Hughes, MD, Michelle Specht, MD, Barbara L. Smith, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 10/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Radiation therapy (RT) after lumpectomy for breast cancer can be delivered with several different regimens. We evaluated a cost-minimization strategy to select among RT options.

Methods

An institutional review board (IRB)-approved retrospective review identified a sample of 100 women who underwent lumpectomy for invasive or in situ breast cancer during 2009. Post lumpectomy RT options included: no radiation in women ≥70 years [T1N0, estrogen receptor (ER)+] per Cancer and Leukemia Group B (CALGB) 9343 (no-RT), accelerated external-beam partial-breast irradiation (APBI), and Canadian fractionation (C-RT), as alternatives to standard whole-breast radiation therapy (WBRT). Eligibility for RT regimens was based on published criteria. RT costs were estimated using the 2011 US Medicare Physician Fee Schedule and average Current Procedural Terminology (CPT) codes billed per regimen at our institution. Costs were modeled in a 1,000-patient theoretical cohort.

Results

Median patient age was 56.5 years (range 32–93 years). Tumor histology included invasive ductal cancer (78 %), ductal carcinoma in situ (DCIS) (15 %), invasive lobular cancer (6 %), and mixed histology (1 %). Median tumor size was 1 cm (range 0.2–5 cm). Estimated per-patient cost of radiation was US$5,341.81 for APBI, US$9,121.98 for C-RT, and US$13,358.37 for WBRT. When patients received the least expensive radiation regimen for which they were eligible, 14 % received no-RT, 44 % received APBI, 7 % received C-RT, and 35 % defaulted to WBRT. Using a cost-minimization strategy, estimated RT costs were US$7.67 million, versus US$13.36 million had all patients received WBRT, representing cost savings of US$5.69 million per 1,000 patients treated.

Conclusions

A cost-minimization strategy results in a 43 % reduction in estimated radiation costs among women undergoing breast conservation.
Literatur
1.
Zurück zum Zitat Arriagada R, Le MG, Rochard F, Contesso G, for the Institut Gustave-Roussy Breast Cancer Group. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. J Clin Oncol. 1996;14 (5):1558–64.PubMed Arriagada R, Le MG, Rochard F, Contesso G, for the Institut Gustave-Roussy Breast Cancer Group. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. J Clin Oncol. 1996;14 (5):1558–64.PubMed
2.
Zurück zum Zitat Veronesi U, Cascinellu N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. NEJM. 2002;347 (16): 1227–32.PubMedCrossRef Veronesi U, Cascinellu N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. NEJM. 2002;347 (16): 1227–32.PubMedCrossRef
3.
Zurück zum Zitat Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. NEJM. 2002;347(16):1233–41.PubMedCrossRef Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. NEJM. 2002;347(16):1233–41.PubMedCrossRef
4.
5.
Zurück zum Zitat Whelan T, MacKenzie R, Julian J, Levine M, Shelley W, Grimard L, et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. JNCI. 2002;94(15):1143–50.PubMedCrossRef Whelan T, MacKenzie R, Julian J, Levine M, Shelley W, Grimard L, et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. JNCI. 2002;94(15):1143–50.PubMedCrossRef
6.
Zurück zum Zitat Whelan T, Pignol J-P, Levine MN, Julian JA, MacKenzie R, Parpia S, et al. Long-term results of hypofractionated radiation therapy for breast cancer. NEJM. 2010;362(6):513–20.PubMedCrossRef Whelan T, Pignol J-P, Levine MN, Julian JA, MacKenzie R, Parpia S, et al. Long-term results of hypofractionated radiation therapy for breast cancer. NEJM. 2010;362(6):513–20.PubMedCrossRef
7.
Zurück zum Zitat Smith, BD, Arthur, DW, Bucholz, TA, et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys. 2009;74 (4):987–1001.PubMedCrossRef Smith, BD, Arthur, DW, Bucholz, TA, et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys. 2009;74 (4):987–1001.PubMedCrossRef
8.
Zurück zum Zitat Beitsch PD, Shaitelman SF, Vicini FA. Accelerated partial breast irradiation. J Surg Oncol. 2011;103:362–8.PubMedCrossRef Beitsch PD, Shaitelman SF, Vicini FA. Accelerated partial breast irradiation. J Surg Oncol. 2011;103:362–8.PubMedCrossRef
9.
Zurück zum Zitat Hughes K, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. NEJM. 2004;351:971–7.PubMedCrossRef Hughes K, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. NEJM. 2004;351:971–7.PubMedCrossRef
10.
Zurück zum Zitat Hughes KS, Schnaper LA, Cirrincione C, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 or older with early breast cancer. 2010 ASCO Annual Meeting. Abstract 507. June 2010. Hughes KS, Schnaper LA, Cirrincione C, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 or older with early breast cancer. 2010 ASCO Annual Meeting. Abstract 507. June 2010.
11.
Zurück zum Zitat Kozak KR, Katz A, Adams J, et al. Dosimetric comparison of proton and photon three-dimensional conformal, external beam accelerated partial breast irradiation techniques. Int J Radiat Oncol Biol Phys. 2006;65:1572–8.PubMedCrossRef Kozak KR, Katz A, Adams J, et al. Dosimetric comparison of proton and photon three-dimensional conformal, external beam accelerated partial breast irradiation techniques. Int J Radiat Oncol Biol Phys. 2006;65:1572–8.PubMedCrossRef
12.
Zurück zum Zitat Suh W, Pierce LJ, Vicini FA, Hayman JA. A cost comparison analysis of partial versus whole-breast irradiation after breast-conserving surgery for early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2005;62 (3):790–6.PubMedCrossRef Suh W, Pierce LJ, Vicini FA, Hayman JA. A cost comparison analysis of partial versus whole-breast irradiation after breast-conserving surgery for early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2005;62 (3):790–6.PubMedCrossRef
13.
Zurück zum Zitat Sher DJ, Wittenberg E, Suh W, Taghian AG, Punglia RS. Partial-breast irradiation versus whole breast irradiation for early-stage breast cancer: a cost-effectiveness analysis. Int J Radiat Oncol Bio Phys. 2009;74(2): 440–6.CrossRef Sher DJ, Wittenberg E, Suh W, Taghian AG, Punglia RS. Partial-breast irradiation versus whole breast irradiation for early-stage breast cancer: a cost-effectiveness analysis. Int J Radiat Oncol Bio Phys. 2009;74(2): 440–6.CrossRef
14.
Zurück zum Zitat Dwyer P, Hickey B, Burmeister E, Burmeister B. Hypofractionated whole-breast radiotherapy: impact on departmental waiting times and cost. J Med Imaging Radiat Oncol. 2010;54:229–34.PubMedCrossRef Dwyer P, Hickey B, Burmeister E, Burmeister B. Hypofractionated whole-breast radiotherapy: impact on departmental waiting times and cost. J Med Imaging Radiat Oncol. 2010;54:229–34.PubMedCrossRef
15.
Zurück zum Zitat Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103(2):117–28.PubMedCrossRef Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103(2):117–28.PubMedCrossRef
16.
Zurück zum Zitat Smith BD, Bentzen SM, Correa CR, Hahn CA, Hardenbergh PH, Ibbott GS, et al. Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol Biol Phys. 2010 Jul 15. Smith BD, Bentzen SM, Correa CR, Hahn CA, Hardenbergh PH, Ibbott GS, et al. Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol Biol Phys. 2010 Jul 15.
17.
Zurück zum Zitat Taghian AG. Dana-Farber/Harvard Cancer Center protocol 03-179; registry number NCT00694577, clinicaltrials.gov. Taghian AG. Dana-Farber/Harvard Cancer Center protocol 03-179; registry number NCT00694577, clinicaltrials.gov.
19.
Zurück zum Zitat Chen PY, Wallace M, Mitchell C, et al. Four-year efficacy, cosmesis, and toxicity using three-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2010;76:91–7.CrossRef Chen PY, Wallace M, Mitchell C, et al. Four-year efficacy, cosmesis, and toxicity using three-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2010;76:91–7.CrossRef
20.
Zurück zum Zitat Vicini FA, Remouchamps V, Wallace M. Ongoing clinical experience utilizing 3D conformal external beam radiotherapy to deliver partial-breast irradiation in patients with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2003;57:1247–53.PubMedCrossRef Vicini FA, Remouchamps V, Wallace M. Ongoing clinical experience utilizing 3D conformal external beam radiotherapy to deliver partial-breast irradiation in patients with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2003;57:1247–53.PubMedCrossRef
22.
Zurück zum Zitat Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998;16:441–52.PubMed Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998;16:441–52.PubMed
23.
Zurück zum Zitat Wong JS, Kaelin CM, Troyan SL, Gadd MA, Gelman R, Lester SC, et al. Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol. 2006;24(7):1031–6.PubMedCrossRef Wong JS, Kaelin CM, Troyan SL, Gadd MA, Gelman R, Lester SC, et al. Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol. 2006;24(7):1031–6.PubMedCrossRef
24.
Zurück zum Zitat Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in situ: ten-year results of European Organisation for Research and Treatment of Cancer Randomized Phase III Trial 10853—a study by the EORTC Breast Cancer Cooperative Group. J Clin Oncol. 2006;24(21):3381–7.PubMedCrossRef Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in situ: ten-year results of European Organisation for Research and Treatment of Cancer Randomized Phase III Trial 10853—a study by the EORTC Breast Cancer Cooperative Group. J Clin Oncol. 2006;24(21):3381–7.PubMedCrossRef
25.
Zurück zum Zitat Houghton J, George WD, Cuzick J, et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia and New Zealand: randomised controlled trial. Lancet. 2003;362:95–102.PubMedCrossRef Houghton J, George WD, Cuzick J, et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia and New Zealand: randomised controlled trial. Lancet. 2003;362:95–102.PubMedCrossRef
26.
Zurück zum Zitat Hughes LL, Wang M, Page DL, Gray R, Solin LJ, Davidson NE, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27:5319–24.PubMedCrossRef Hughes LL, Wang M, Page DL, Gray R, Solin LJ, Davidson NE, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27:5319–24.PubMedCrossRef
28.
Zurück zum Zitat Coopey SB, Buckley JM, Smith BL, Hughes KS, Gadd MA, Specht MC. Lumpectomy cavity shaved margins do not impact re-excision rates in breast cancer patients. Ann Surg Oncol. 2011;18:3036–40.PubMedCrossRef Coopey SB, Buckley JM, Smith BL, Hughes KS, Gadd MA, Specht MC. Lumpectomy cavity shaved margins do not impact re-excision rates in breast cancer patients. Ann Surg Oncol. 2011;18:3036–40.PubMedCrossRef
Metadaten
Titel
Cost Comparison of Radiation Treatment Options After Lumpectomy for Breast Cancer
verfasst von
Rachel A. Greenup, MD, MPH
Melissa S. Camp, MD, MPH
Alphonse G. Taghian, MD, PhD
Julliette Buckley, MD
Suzanne B. Coopey, MD
Michele Gadd, MD
Kevin Hughes, MD
Michelle Specht, MD
Barbara L. Smith, MD, PhD
Publikationsdatum
01.10.2012
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 10/2012
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-012-2546-5

Weitere Artikel der Ausgabe 10/2012

Annals of Surgical Oncology 10/2012 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.